| Dr John M Joseph, MD | |
|
2008 E Hebron Pkwy, Suite 100, Carrollton, TX 75007-1602 | |
| (972) 492-8700 | |
| (972) 395-1140 |
| Full Name | Dr John M Joseph |
|---|---|
| Gender | Male |
| Speciality | Rheumatology |
| Experience | 48 Years |
| Location | 2008 E Hebron Pkwy, Carrollton, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1477505980 | NPI | - | NPPES |
| 098399102 | Medicaid | TX |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RR0500X | Internal Medicine - Rheumatology | G2426 (Texas) | Primary |
| Entity Name | John M Joseph Md Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1609825843 PECOS PAC ID: 1052540689 Enrollment ID: O20140131000698 |
News Archive
A new study reveals that in the prediction of treatment outcome for castration-resistant prostate cancer, a change in circulating tumour cells detection might be more accurate than the change in prostate-specific antigen levels. The findings of this award-winning study were presented at the recent EAU 13th Central European Meeting in Prague.
Carnegie Mellon University scientists have employed biological molecules to create a microgel that could recover costly enzymes for repeated use in catalyzing commercially important reactions. The microgel could potentially recover any enzyme and theoretically save manufacturers considerable money.
CureDM, LLC announced today that an agreement has been signed with Sanofi-Aventis for the exclusive worldwide license of Pancreate™, a novel islet neogenesis agent for the treatment of type 1 and type 2 diabetes. CureDM is a privately held biopharmaceutical company whose scientists discovered Pancreate™, a first-in-class human peptide therapeutic. Several key Composition of Matter and Use patents have been issued to CureDM for this potentially transforming treatment approach for diabetes.
AMAG Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease, today reported unaudited consolidated financial results for the first quarter ended March 31, 2010.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr John M Joseph, MD 2008 E Hebron Pkwy, Suite 100, Carrollton, TX 75007-1602 Ph: (972) 492-8700 | Dr John M Joseph, MD 2008 E Hebron Pkwy, Suite 100, Carrollton, TX 75007-1602 Ph: (972) 492-8700 |
News Archive
A new study reveals that in the prediction of treatment outcome for castration-resistant prostate cancer, a change in circulating tumour cells detection might be more accurate than the change in prostate-specific antigen levels. The findings of this award-winning study were presented at the recent EAU 13th Central European Meeting in Prague.
Carnegie Mellon University scientists have employed biological molecules to create a microgel that could recover costly enzymes for repeated use in catalyzing commercially important reactions. The microgel could potentially recover any enzyme and theoretically save manufacturers considerable money.
CureDM, LLC announced today that an agreement has been signed with Sanofi-Aventis for the exclusive worldwide license of Pancreate™, a novel islet neogenesis agent for the treatment of type 1 and type 2 diabetes. CureDM is a privately held biopharmaceutical company whose scientists discovered Pancreate™, a first-in-class human peptide therapeutic. Several key Composition of Matter and Use patents have been issued to CureDM for this potentially transforming treatment approach for diabetes.
AMAG Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease, today reported unaudited consolidated financial results for the first quarter ended March 31, 2010.
› Verified 4 days ago
Dr. Ketan P Patel, M.D. Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 4325 N Josey Ln Ste 202, Carrollton, TX 75010 Phone: 214-566-9616 Fax: 307-459-6599 | |
Dr. Melissa Lasola Tompkins, M.D. Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 4333 N Josey Ln, Suite 207, Carrollton, TX 75010 Phone: 972-394-2971 Fax: 972-492-1261 | |
Hardeep S Rai, MD Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 1913 Walnut Plz, Carrollton, TX 75006 Phone: 972-416-5902 | |
Arun Jacob, MD Rheumatology Medicare: May Accept Medicare Assignments Practice Location: 1213 E Trinity Mills Rd Ste 173, Carrollton, TX 75006 Phone: 972-962-1296 | |
Dr. Rufino Gerona Talatala, MD Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 4221 Medical Pkwy, Bldg 200, Suite 250, Carrollton, TX 75010 Phone: 972-492-0333 Fax: 972-394-6585 | |
Dr. Hussein Somani, MD Rheumatology Medicare: Not Enrolled in Medicare Practice Location: 1636 Flowers Dr, Carrollton, TX 75007 Phone: 847-932-9235 | |
Harjodh Singh Puar, M.D. Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 2761 E Trinity Mills Rd, Suite 100, Carrollton, TX 75006 Phone: 972-478-7300 Fax: 972-478-7304 |